Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach
- Soligenix is entering a pivotal period marked by several anticipated clinical readouts and milestones expected throughout 2026.
- At the heart of the Zacks analysis is HyBryte(TM), which Soligenix is evaluating in the Phase 3 FLASH2 study for the treatment of CTCL.
- Beyond HyBryte, the report also points to progress involving SGX945, or dusquetide, for Behçet’s disease.
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing therapies for rare diseases and unmet medical needs, is featured in a detailed research report issued by Zacks Small-Cap Research. The March 12 report provides a comprehensive look at the company’s pipeline, financial positioning and upcoming clinical catalysts, underscoring the potential value proposition for investors as Soligenix advances multiple programs toward key inflection points.
According to Zacks, Soligenix is entering a pivotal period marked by several anticipated clinical readouts and milestones expected throughout 2026. Central to this outlook is the company’s ongoing Phase 3 FLASH2 trial evaluating HyBryte(TM) (“SGX301”), SNGX’s lead therapeutic candidate for the treatment of early-stage cutaneous T-cell lymphoma (“CTCL”). The report notes that an interim analysis is expected in the second quarter of 2026, with topline results anticipated later in the year, positioning the program as a near-term value driver for the company.
At the heart of the Zacks analysis is HyBryte(TM), also known as SGX301 or synthetic hypericin, which Soligenix is evaluating in the confirmatory Phase 3 FLASH2 study for the treatment of CTCL. According to the report, the company had enrolled 66 of the planned 80 patients as of the latest update, and Zacks expects an interim analysis in the second quarter of 2026, followed by topline results in the second half of 2026. The report notes that the FLASH2 study is similar in design to the prior successful Phase 3 FLASH trial, but with an important difference: In FLASH2, patients receive 18 consecutive weeks of treatment before the primary efficacy endpoint is assessed, whereas the earlier trial measured the endpoint after the first six-week treatment cycle.
One of the most notable points in the Zacks report is its discussion of the blinded aggregate response rate from FLASH2. Zacks says the overall blinded aggregate response rate remains consistent with what Soligenix reported in November 2025, at 48% for all patients who had completed the treatment phase of the study. That figure is materially higher than the 25% overall response rate used to design and power the trial, leading Zacks to say its confidence is high that the study will have a positive readout. The report goes further, explaining that if the placebo response rate is near the 10% rate used in the trial assumptions, then the active-treatment arm would likely need to be producing a very strong response to yield a combined blinded rate of 48%. Zacks does note that the exact numbers will not be known until the data are unblinded, but it views the update as a strong sign that the study is trending in the right direction.
Beyond HyBryte, the report also points to progress involving SGX945, or dusquetide, for Behçet’s disease. Zacks highlights two recent regulatory developments. First, in February 2026, the European Medicines Agency’s Committee for Orphan Medicinal Products gave a positive recommendation on Soligenix’s request for orphan drug designation for SGX945 in Behçet’s disease, with European Commission ratification still pending. According to the report, orphan drug designation in the European Union would provide 10 years of marketing exclusivity following approval, along with other development-related incentives.
Second, the Zacks report reports that on March 10, 2026, the UK Medicines and Healthcare Products Regulatory Agency granted Promising Innovative Medicine designation to SGX945 for Behçet’s disease. Zacks describes that designation as the initial step toward possible inclusion in the UK Early Access to Medicines Scheme, which is designed to help severely ill patients access promising therapies earlier than would otherwise be possible. These regulatory developments suggest that Zacks sees SGX945 as another meaningful value driver in the Soligenix pipeline.
The report also references SGX302, Soligenix’s psoriasis program. In its conclusion, Zacks says it expects updates in 2026 not only for the Behçet’s disease program with SGX945 but also for SGX302 following encouraging topline results from a phase 2a trial in mild-to-moderate psoriasis. That gives investors more than one clinical storyline to watch as the year unfolds.
On valuation, Zacks states that its $25 per share estimate is based on a probability-adjusted discounted cash flow model that incorporates potential future revenues from HyBryte, SGX302 and SGX945. The firm notes that the model is highly dependent on the continued clinical success of Soligenix’s pipeline and would be adjusted based on future clinical results.
Financially, the report’s projected financial tables show no product revenue contribution yet from HyBryte. The same tables include a “Public Health Solutions” line item, but there is no substantive discussion of that segment in the report’s narrative. That makes the main takeaway of this Zacks note clear: the report is primarily about Soligenix’s upcoming CTCL readouts, its Behçet’s disease regulatory momentum, and continuing advancement of its psoriasis program.
Overall, the Zacks Small-Cap Research report paints a picture of a company at an important inflection point. With several clinical catalysts on the horizon and a lead program that has already demonstrated encouraging efficacy signals, Soligenix is positioned to potentially deliver meaningful advancements in rare disease treatment while creating value for shareholders. As 2026 unfolds, the company’s progress in the clinic will likely remain a focal point for investors and industry observers alike, as Soligenix continues its efforts to bring innovative therapies to patients in need.
For more information, visit www.Soligenix.com.
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://nnw.fm/SNGX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- Soligenix is entering a pivotal period marked by several anticipated clinical readouts and milestones expected throughout 2026.
- At the heart of the Zacks analysis is HyBryte(TM), which Soligenix is evaluating in the Phase 3 FLASH2 study for the treatment of CTCL.
- Beyond HyBryte, the report also points to progress involving SGX945, or dusquetide, for Behçet’s disease.
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing therapies for rare diseases and unmet medical needs, is featured in a detailed research report issued by Zacks Small-Cap Research. The March 12 report provides a comprehensive look at the company’s pipeline, financial positioning and upcoming clinical catalysts, underscoring the potential value proposition for investors as Soligenix advances multiple programs toward key inflection points.
According to Zacks, Soligenix is entering a pivotal period marked by several anticipated clinical readouts and milestones expected throughout 2026. Central to this outlook is the company’s ongoing Phase 3 FLASH2 trial evaluating HyBryte(TM) (“SGX301”), SNGX’s lead therapeutic candidate for the treatment of early-stage cutaneous T-cell lymphoma (“CTCL”). The report notes that an interim analysis is expected in the second quarter of 2026, with topline results anticipated later in the year, positioning the program as a near-term value driver for the company.
At the heart of the Zacks analysis is HyBryte(TM), also known as SGX301 or synthetic hypericin, which Soligenix is evaluating in the confirmatory Phase 3 FLASH2 study for the treatment of CTCL. According to the report, the company had enrolled 66 of the planned 80 patients as of the latest update, and Zacks expects an interim analysis in the second quarter of 2026, followed by topline results in the second half of 2026. The report notes that the FLASH2 study is similar in design to the prior successful Phase 3 FLASH trial, but with an important difference: In FLASH2, patients receive 18 consecutive weeks of treatment before the primary efficacy endpoint is assessed, whereas the earlier trial measured the endpoint after the first six-week treatment cycle.
One of the most notable points in the Zacks report is its discussion of the blinded aggregate response rate from FLASH2. Zacks says the overall blinded aggregate response rate remains consistent with what Soligenix reported in November 2025, at 48% for all patients who had completed the treatment phase of the study. That figure is materially higher than the 25% overall response rate used to design and power the trial, leading Zacks to say its confidence is high that the study will have a positive readout. The report goes further, explaining that if the placebo response rate is near the 10% rate used in the trial assumptions, then the active-treatment arm would likely need to be producing a very strong response to yield a combined blinded rate of 48%. Zacks does note that the exact numbers will not be known until the data are unblinded, but it views the update as a strong sign that the study is trending in the right direction.
Beyond HyBryte, the report also points to progress involving SGX945, or dusquetide, for Behçet’s disease. Zacks highlights two recent regulatory developments. First, in February 2026, the European Medicines Agency’s Committee for Orphan Medicinal Products gave a positive recommendation on Soligenix’s request for orphan drug designation for SGX945 in Behçet’s disease, with European Commission ratification still pending. According to the report, orphan drug designation in the European Union would provide 10 years of marketing exclusivity following approval, along with other development-related incentives.
Second, the Zacks report reports that on March 10, 2026, the UK Medicines and Healthcare Products Regulatory Agency granted Promising Innovative Medicine designation to SGX945 for Behçet’s disease. Zacks describes that designation as the initial step toward possible inclusion in the UK Early Access to Medicines Scheme, which is designed to help severely ill patients access promising therapies earlier than would otherwise be possible. These regulatory developments suggest that Zacks sees SGX945 as another meaningful value driver in the Soligenix pipeline.
The report also references SGX302, Soligenix’s psoriasis program. In its conclusion, Zacks says it expects updates in 2026 not only for the Behçet’s disease program with SGX945 but also for SGX302 following encouraging topline results from a phase 2a trial in mild-to-moderate psoriasis. That gives investors more than one clinical storyline to watch as the year unfolds.
On valuation, Zacks states that its $25 per share estimate is based on a probability-adjusted discounted cash flow model that incorporates potential future revenues from HyBryte, SGX302 and SGX945. The firm notes that the model is highly dependent on the continued clinical success of Soligenix’s pipeline and would be adjusted based on future clinical results.
Financially, the report’s projected financial tables show no product revenue contribution yet from HyBryte. The same tables include a “Public Health Solutions” line item, but there is no substantive discussion of that segment in the report’s narrative. That makes the main takeaway of this Zacks note clear: the report is primarily about Soligenix’s upcoming CTCL readouts, its Behçet’s disease regulatory momentum, and continuing advancement of its psoriasis program.
Overall, the Zacks Small-Cap Research report paints a picture of a company at an important inflection point. With several clinical catalysts on the horizon and a lead program that has already demonstrated encouraging efficacy signals, Soligenix is positioned to potentially deliver meaningful advancements in rare disease treatment while creating value for shareholders. As 2026 unfolds, the company’s progress in the clinic will likely remain a focal point for investors and industry observers alike, as Soligenix continues its efforts to bring innovative therapies to patients in need.
For more information, visit www.Soligenix.com.
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://nnw.fm/SNGX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
